General Pension Society Pzu Joint Stock CO Kymera Therapeutics, Inc. Transaction History

General Pension Society Pzu Joint Stock CO

$326 Billion
Q4 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2021 Mar 13, 2025	SELL	$47.8 - $66.66 $143,400 - $199,980	-3,000 Reduced 37.5%	5,000 $294 Million
Q2 2021 Mar 13, 2025	BUY	$31.08 - $51.95 $248,640 - $415,600	8,000 New	8,000 $388 Million

Others Institutions Holding KYMR

# of Institutions

186

Shares Held

65.6M

Call Options Held

49.6K

Put Options Held

17K

Price T Rowe Associates Inc Baltimore, MD

6.87M
Shares

$224 Million
0.03% of portfolio
Baker Bros. Advisors LP New York, NY

6M
Shares

$195 Million
2.67% of portfolio
Wellington Management Group LLP Boston, MA

5.31M
Shares

$173 Million
0.04% of portfolio
Bvf Inc San Francisco, CA

5.16M
Shares

$168 Million
7.77% of portfolio
Avoro Capital Advisors LLC New York, NY

5.15M
Shares

$168 Million
3.02% of portfolio

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $1.78B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of General Pension Society Pzu Joint Stock CO, based on Form 13F filings with the SEC.

News

Stay updated on General Pension Society Pzu Joint Stock CO with notifications on news.

Account